My Participation in the ERS Congress 2024
The ERS Congress 2024 in Vienna attracted close to 20,000 delegates, both onsite and online, making it a vibrant and dynamic event focused on advancing respiratory health.
EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).
Report from the International PHA conference
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients, and advocates from around the world, all united by a shared commitment to advancing the understanding and treatment of pulmonary
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).
Report from SAPH2024
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured an impressive scientific program with sessions led by numerous leading PH specialists from around the world.
Report from the IMPACHT conference in Barcelona June 30th – July 1st
Ferrer annually hosts a conference known as IMPACHT (International Meeting on Pulmonary Hypertension Clinical Treatment) that caters to pulmonologists and cardiologists.
EU Commission meeting
The EU Commission invite stakeholders to a meeting to discussed the revision of the pharmaceutical legislation. The general director of SG SANTE lead the meeting.
EPF’s 20 years anniversary + AGM
European Patients’ Forum turned 20 years in 2023. This was marked with an event in Brussels where members, industry and others were invited. (PHA Europe is a full member.) The next day they ran their Annual General Meeting.
Mariposa Journal – 2022 winter N.29
Dear Friends, Colleagues and Supporters, It is always a great pleasure to look back and see the ample accomplishments of the past year. From the previous, summer edition of Mariposa, you could learn about our efforts and success to celebrate the 10th anniversary of World